- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
Inducible T-cell costimulator ligand (ICOSLG) is a membrane-associated immune regulatory protein that functions as a critical mediator of adaptive immune activation and T-cell costimulation signaling. ICOSL Antibody / T-Cell Costimulation Marker is useful for studying immune checkpoint biology, antigen-presenting cell interactions, and lymphocyte activation pathways associated with adaptive immunity and tumor immunology. ICOSL antibody, also referred to as ICOS ligand antibody, CD275 antibody, B7-H2 antibody, and B7RP-1 antibody in the literature, recognizes a B7 family costimulatory ligand that binds the inducible T-cell costimulator receptor (ICOS) expressed on activated T lymphocytes.
ICOSLG is predominantly expressed on antigen-presenting cells including dendritic cells, macrophages, monocytes, and activated B cells, although expression has also been reported in endothelial cells, epithelial tissues, fibroblasts, and selected tumor microenvironments. The protein is primarily localized to the plasma membrane where it participates in immune synapse formation and communication between antigen-presenting cells and T lymphocytes. Engagement of ICOS by ICOSLG promotes T-cell proliferation, cytokine secretion, survival signaling, and differentiation of follicular helper T cells involved in germinal center maintenance and antibody-mediated immunity. Through these functions, ICOSLG contributes to regulation of adaptive immune responses and maintenance of immune homeostasis.
ICOS-ICOSLG signaling has emerged as an important regulatory axis in cancer immunology and immune checkpoint research. Altered expression of ICOSLG within the tumor microenvironment may influence T-cell exhaustion, immune evasion, inflammatory signaling, and responsiveness to checkpoint-directed immunotherapies. Increased interest in this pathway has led to expanding investigation of ICOSLG expression across tumor-associated immune infiltrates, stromal compartments, and epithelial malignancies. Because ICOSLG functions as a costimulatory checkpoint ligand, the target is highly relevant for studies focused on antitumor immunity, immune regulation, and therapeutic modulation of adaptive immune signaling pathways.
In addition to oncology applications, ICOSLG has been implicated in autoimmune disease, chronic inflammatory disorders, infectious disease responses, and regulation of humoral immunity. ICOSLG-mediated signaling contributes to B-cell and T-cell communication networks associated with cytokine regulation, germinal center architecture, and maintenance of activated lymphocyte populations. Dysregulated signaling through the ICOS pathway has been associated with abnormal inflammatory responses and altered immune tolerance mechanisms, supporting continued interest in ICOSLG as a marker of adaptive immune activation and immune checkpoint function.
Immunohistochemistry, immunofluorescence, and flow cytometry studies commonly demonstrate membranous and cytoplasmic staining patterns consistent with expression in activated immune cell populations and epithelial tissues involved in adaptive immune interactions. A mouse monoclonal clone ICOSL/3111 antibody can be used for immunofluorescence, flow cytometry, immunohistochemistry, and protein microarray specificity validation studies examining T-cell costimulation pathways and immune checkpoint signaling networks. Because ICOSLG functions at the interface of antigen presentation and adaptive immune regulation, this target remains highly relevant for studies investigating lymphocyte activation, tumor immunology, and immune communication mechanisms.
Researchers investigating immune checkpoint signaling, antigen-presenting cell biology, and adaptive immune activation pathways may also be interested in our broader Immunology Antibodies collection featuring targets involved in T-cell regulation, cytokine signaling, and tumor immunology research.
Optimal dilution of the ICOSL Antibody / T-Cell Costimulation Marker should be determined by the researcher.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
A recombinant fragment of human ICOS Ligand / B7RP-1 protein within amino acids 23-149 was used as the immunogen for the ICOSLG / ICOSL antibody.
Store the ICOSLG / ICOSL antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
ICOS ligand antibody, ICOSLG antibody, CD275 antibody, B7-H2 antibody, B7RP-1 antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.